CN104370832B - 一种川芎嗪的制备方法 - Google Patents
一种川芎嗪的制备方法 Download PDFInfo
- Publication number
- CN104370832B CN104370832B CN201410548902.9A CN201410548902A CN104370832B CN 104370832 B CN104370832 B CN 104370832B CN 201410548902 A CN201410548902 A CN 201410548902A CN 104370832 B CN104370832 B CN 104370832B
- Authority
- CN
- China
- Prior art keywords
- solution
- temperature
- ligustrazine
- water
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 50
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 claims abstract description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 238000003756 stirring Methods 0.000 claims abstract description 39
- 239000003054 catalyst Substances 0.000 claims abstract description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 25
- 239000000706 filtrate Substances 0.000 claims abstract description 24
- 239000000463 material Substances 0.000 claims abstract description 24
- 239000013078 crystal Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000019257 ammonium acetate Nutrition 0.000 claims abstract description 13
- 239000005695 Ammonium acetate Substances 0.000 claims abstract description 6
- 229940043376 ammonium acetate Drugs 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 238000002425 crystallisation Methods 0.000 claims abstract description 5
- 230000008025 crystallization Effects 0.000 claims abstract description 5
- 238000005899 aromatization reaction Methods 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 47
- 239000004615 ingredient Substances 0.000 claims description 33
- 238000005292 vacuum distillation Methods 0.000 claims description 24
- 229960000583 acetic acid Drugs 0.000 claims description 23
- XWNSFEAWWGGSKJ-UHFFFAOYSA-N 4-acetyl-4-methylheptanedinitrile Chemical compound N#CCCC(C)(C(=O)C)CCC#N XWNSFEAWWGGSKJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000004153 Potassium bromate Substances 0.000 claims description 22
- 239000012362 glacial acetic acid Substances 0.000 claims description 22
- 229940094037 potassium bromate Drugs 0.000 claims description 22
- 235000019396 potassium bromate Nutrition 0.000 claims description 22
- 239000008236 heating water Substances 0.000 claims description 12
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 11
- 229940079827 sodium hydrogen sulfite Drugs 0.000 claims description 11
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 230000008719 thickening Effects 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
- 238000004821 distillation Methods 0.000 abstract description 5
- 238000000605 extraction Methods 0.000 abstract description 3
- 230000035484 reaction time Effects 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000004134 energy conservation Methods 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- IQZZQVQXKNOQAX-UHFFFAOYSA-N 3-aminobut-3-en-2-one Chemical class CC(=O)C(N)=C IQZZQVQXKNOQAX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 2
- QQZWEECEMNQSTG-UHFFFAOYSA-N Ethyl nitrite Chemical compound CCON=O QQZWEECEMNQSTG-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000112528 Ligusticum striatum Species 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 238000011953 bioanalysis Methods 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- GHWVXCQZPNWFRO-UHFFFAOYSA-N butane-2,3-diamine Chemical compound CC(N)C(C)N GHWVXCQZPNWFRO-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960004643 cupric oxide Drugs 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
实施例 | 3-羟基-2-丁酮投入量 | 川芎嗪理论产量 | 川芎嗪实际产量 | 收率 |
实施例1 | 21份 | 16.22份 | 14.05份 | 86.6% |
实施例2 | 19.7份 | 15.22份 | 13.13份 | 86.3% |
实施例3 | 20.3份 | 15.69份 | 13.59份 | 86.6% |
实施例4 | 19份 | 14.68份 | 12.80份 | 87.2% |
实施例5 | 20份 | 15.45份 | 13.46份 | 87.1% |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410548902.9A CN104370832B (zh) | 2014-10-16 | 2014-10-16 | 一种川芎嗪的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410548902.9A CN104370832B (zh) | 2014-10-16 | 2014-10-16 | 一种川芎嗪的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104370832A CN104370832A (zh) | 2015-02-25 |
CN104370832B true CN104370832B (zh) | 2017-02-15 |
Family
ID=52550068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410548902.9A Active CN104370832B (zh) | 2014-10-16 | 2014-10-16 | 一种川芎嗪的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104370832B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11091446B2 (en) | 2017-03-24 | 2021-08-17 | R.J. Reynolds Tobacco Company | Methods of selectively forming substituted pyrazines |
CN107857736A (zh) * | 2017-12-19 | 2018-03-30 | 濮阳天源生物科技有限公司 | 一种清洁的四甲基吡嗪制备方法 |
CN108892645B (zh) * | 2018-09-15 | 2021-07-13 | 广州方中化工有限公司 | 一种制备四甲基吡嗪的方法 |
-
2014
- 2014-10-16 CN CN201410548902.9A patent/CN104370832B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104370832A (zh) | 2015-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104370832B (zh) | 一种川芎嗪的制备方法 | |
CN109705013B (zh) | 一种1-(4-甲基苄基)-3-氨基-4-甲硒基马来酰亚胺化合物及制备方法 | |
CN103087059B (zh) | 一种高纯度盐酸奥普力农的制备方法 | |
CN113861146A (zh) | 一种天然δ-癸内酯的合成工艺 | |
CN104761508A (zh) | 一种川芎嗪的高收率制备方法 | |
CN111320586B (zh) | 一种厄洛替尼的合成方法 | |
CN105254556B (zh) | 一种制备匹可硫酸钠的方法 | |
CN107602400A (zh) | 一种加快甲芬那酸合成时间的方法 | |
CN110841075A (zh) | 一种丹皮酚包合物的制备方法 | |
CN102127089B (zh) | 一种喜树碱的提取方法 | |
CN110862429A (zh) | 一种七叶皂苷钠的制备方法 | |
CN105712872A (zh) | 一种从王浆渣中提取蜂王酸的工艺方法 | |
CN106632549A (zh) | 一种离子液体提取柚子皮中柚皮甙的方法 | |
CN109971813A (zh) | 一种制备双降醇的工艺 | |
CN103951675A (zh) | 一种硫酸氢氯吡格雷的制备方法 | |
CN111362902B (zh) | 一种洋茉莉醛的制备方法 | |
CN108069972A (zh) | 一种双嘧达莫原料药的生产方法 | |
CN106478516A (zh) | 一种5‑氯哒嗪酮的合成方法 | |
CN106336439A (zh) | 一种二丁酰环磷酸腺苷钙的制备方法 | |
CN112028759A (zh) | 一种获得高含量及高纯度紫草素的制备方法 | |
CN104744470A (zh) | 一种茶碱的合成方法 | |
CN101455399A (zh) | 利用青稞麸皮油制备亚油酸的方法 | |
CN106336401A (zh) | 一种阿伐那非的精制方法 | |
CN108101738A (zh) | 一种3-丁烯-1-醇 | |
CN107602376A (zh) | 一种曲列前尼尔的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: Xifei River Road Changfeng Shuangfeng Economic Development Zone of Hefei City, Anhui Province, No. 008 230000 Patentee after: PINGGUANG PHARMACEUTICAL Co.,Ltd. Address before: Xifei River Road Changfeng Shuangfeng Economic Development Zone of Hefei City, Anhui Province, No. 008 230000 Patentee before: HEFEI PINGGUANG PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method of ligustrazine Effective date of registration: 20170814 Granted publication date: 20170215 Pledgee: Huizhou Merchants Bank Changfeng branch Pledgor: PINGGUANG PHARMACEUTICAL Co.,Ltd. Registration number: 2017340000146 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180813 Granted publication date: 20170215 Pledgee: Huizhou Merchants Bank Changfeng branch Pledgor: PINGGUANG PHARMACEUTICAL Co.,Ltd. Registration number: 2017340000146 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Preparation Method of Ligustrazine Granted publication date: 20170215 Pledgee: Bank of China Changfeng Branch Pledgor: PINGGUANG PHARMACEUTICAL Co.,Ltd. Registration number: Y2024980005951 |